|
Protocol and Consent Forms
Last Updated: July 1, 2009
NOTE: Limited funding may be available to offset costs on certain protocols. Contact KCCOP for more information.
Bone Marrow Transplant
Also, see Cancer Control section for symptom
management/prevention trials.
CALGB C10001: Protocol Summary |
Donor Consent |
Recipient Consent
ALL, Ph+, complete remission after tx on CALGB 10102;
Sequential Chemo+Gleevec+Transplantation (Only SLH is currently approved
for BMT. QARC approval required for TBI.)
CALGB 100104:
Protocol Summary |
Consent Form
MM, Durie-Salmon Stg >1, stable or responsive to >2 mos of any
induction therapy; Autologous
PBSCT ! Maintenance CC-5013/placebo (Only SLH is currently
approved for BMT.)
TOP
Brain/CNS
Also, see Cancer Control section for symptom
management/prevention trials.
Glioma
RTOG 0424: Protocol Summary |
Consent Form
ASTROCYTOMA, OLIGODENDROGLIOMA, or OLIGOASTROCYTOMA, High Risk, Low Grade;
Temozolomide + RT ! Temozolomide x 12 wks
RTOG 0825: Protocol Summary |
Consent Form
GLIOMA, Glioblastoma or Gliosarcoma (Grade IV), newly dx; Central Path Review, Conventional Concurrent Chemoradiation + Adjuv Temozolomide + Bevacizumab/placebo (double-blind)
(see RT & Neurocognitive Function Testing requirements in protocol)
RTOG 0627: Protocol Summary |
Consent Form
GLIOMA, glioblastoma multiforme or gliosarcoma,
recur, prior RT & Temozolomide required; Eval of Dasatinib
MDA 2004-0662: Protocol Summary |
Consent Form
GLIOMA, glioblastoma multiforme, post-op or post-bx RT required; Temozolomide Alone vs Temozolomide in combination w/permutations of Thalidomide, Isotretinoin, &/or Celecoxib
(Investigator & RN must complete STEPS regist – contact KCCOP)
Other
CALGB 50202: Protocol Summary |
Consent Form
CNS, Prim, no NH, prev untreated; Intensive Chemo &
Immunotherapy
RTOG 0227: Protocol Summary | Consent Form
CNS Lymphoma (Prim, B-cell, CD20+); Pre-RT Chemo (Methotrexate + Rituximab + Temozolomide) & Post-RT Temozolomide
Breast
Also, see
Cancer Control section for symptom
management/prevention trials.
Stage 0
NSABP B-43:
Protocol Summary |
Pre-Entry HER2 Test Consent Form |
Consent Form
Adj., Stg 0 (DCIS
or mixed DCIS/LCIS), post-lumpectomy, HER2+; RT +/- concurrent Trastuzumab
CTSU PACCT-1: Protocol Summary |
Consent Form
Adj., Stgs 0, I , Selected II, Hormone+, N0, Candidate for cytotoxic + hormonal therapy; Trial of Individualized Options for Tx (TAILORx Trial)
NSABP B-39: Protocol Summary |
Consent Form
Adj., Stg. 0, I, II; Conventional Whole Breast RT vs Partial Breast RT (Multi-Catheter, Mammosite, or 3D-CRT)
(Sites need approval - check RT requirements in protocol.)
Stage I
CTSU PACCT-1: Protocol Summary |
Consent Form
Adj., Stgs 0, I , Selected II, Hormone+, N0, Candidate for cytotoxic + hormonal therapy; Trial of Individualized Options for Tx (TAILORx Trial)
IBCSG 25-02: Protocol Summary |
Consent Form |
Addendum Consent Form (pts randomized prior
to
1/1/08)
Adj., T1-3, N0-2, M0, Pre-meno, ER+ &/or PgR+; Triptorelin + TMX x 5 yr vs
Triptorelin + Exemestane x 5 yrs (both arms +/- adjuv chemo)
IBCSG 24-02:
Protocol Summary |
Consent Form
Adj.,
Premenopausal, Stgs I, II, & + int mamm nodes by SN (not enlarged), ER &/or
PgR+; Prim Surg ! TMX vs Ovarian Func Suppr + TMX vs Ovarian Func Suppr +
Exemestane (Currently open only at SLH. Other sites – contact KCCOP to begin regulatory process.)
NSABP B-44-I: Protocol Summary |
Pre-Randomization (HER2) Consent |
Treatment Consent Form
Adj., Stgs I-III, HER2(+), Node(+) or High Risk Node(-);
Taxol + Carboplatin + Trastuzumab
! Trastuzumab +/-
Bevacizumab (Industry trial - participation limited to 2 institutions –
only SLH currently approved.)
NSABP B-42: Protocol Summary |
Consent Form
Adj. or Neoadj., Stg I, II, IIIA (rcvd. neoadjuv chemo) or prim tumor T1-3
& ipsilateral nodes pN0-pN3b (rcvd. adjuv chemo), ER+ &/or PgR+, post-meno, completed 5 yrs Arom Inhib
or Tamox + AI; Letrozole vs placebo for prolonging survival
CALGB 40101: Protocol Summary |
Consent Form
Adj., T1‑4, N0-3, M0; Cyclophosphamide + Doxorubicin vs Paclitaxel
SWOG S0307: Protocol Summary |
Consent Form
Adj., Stg I, II, III, Zoledronic Acid vs Clodronate vs Ibandronate (+ standard adjuv tx)
SWOG S0221: Protocol Summary |
Consent Form
Adj., Stg I, II, III, Node+ or Hi-Risk
Node -, male pts allowed; Continuous Schedule Doxorubicin+Cyclophosphade+GCSF vs q2wk Doxorubicin+Cyclophosphade,
both ! Taxol
(q2wks vs weekly x 12 wks)
NSABP B-39: Protocol Summary |
Consent Form
Adj., Stg. 0, I, II; Conventional Whole Breast RT vs Partial Breast RT (Multi-Catheter, Mammosite, or 3D-CRT)
(Sites need approval - check RT requirements in protocol.)
CTSU N063D:
Protocol Summary |
Consent Form
(Neo-)Adj., known ER/PgR or ER, HER2+, must have rcvd
>4 cycles of
anthracycline-based (neo-)adj chemo;
Eval of
sequences of Lapatinib &/or Trastuzumab (randomized
arms). Effective 3/15/09, Design 1 is closed.
Stage II
CTSU PACCT-1: Protocol Summary |
Consent Form
Adj., Stgs 0, I , Selected II, Hormone+, N0, Candidate for cytotoxic + hormonal therapy; Trial of Individualized Options for Tx (TAILORx Trial)
IBCSG 25-02: Protocol Summary |
Consent Form |
Addendum Consent Form (pts randomized prior
to
1/1/08)
Adj., T1-3, N0-2, M0, Pre-meno, ER+ &/or PgR+; Triptorelin + TMX x 5 yr vs
Triptorelin + Exemestane x 5 yrs (both arms +/- adjuv chemo)
IBCSG 24-02:
Protocol Summary |
Consent Form
Adj.,
Premenopausal, Stgs I, II, & + int mamm nodes by SN (not enlarged), ER &/or
PgR+; Prim Surg ! TMX vs Ovarian Func Suppr + TMX vs Ovarian Func Suppr +
Exemestane (Currently open only at SLH. Other sites – contact KCCOP to begin regulatory process.)
NSABP B-44-I: Protocol Summary |
Pre-Randomization (HER2) Consent |
Treatment Consent Form
Adj., Stgs I-III, HER2(+), Node(+) or High Risk Node(-);
Taxol + Carboplatin + Trastuzumab
! Trastuzumab +/-
Bevacizumab (Industry trial - participation limited to 2 institutions –
only SLH currently approved.)
CTSU N063D:
Protocol Summary |
Consent Form
(Neo-)Adj., known ER/PgR or ER, HER2+, must have rcvd
>4 cycles of
anthracycline-based (neo-)adj chemo;
Eval of
sequences of Lapatinib &/or Trastuzumab (randomized
arms). Effective 3/15/09, Design 1 is closed.
ACOSOG Z1031:
Protocol Summary |
Consent Form
Supplemental Sample Consent |
Optional Genome Research Consent
Neoadj., T2-4c, any N, M0, Post-meno, ER+; 16-18 wks Exemestane vs Letrozole vs Anastrozole
NSABP B-41:
Protocol Summary |
Consent Form
Neoadj.,
Stgs IIA-B & selected Stg IIIA, HER2+, palpable & operable; AC
! Taxol +
Trastuzumab vs AC
! Taxol + Lapatinib vs
AC
! Taxol + Trastuzumab + Lapatinib
(all Arms followed by Surg & post-surg Trastuzumab, & required correlative
studies for path CR)
NSABP B-42: Protocol Summary |
Consent Form
Adj. or Neoadj., Stg I, II, IIIA (rcvd. neoadjuv chemo) or prim tumor T1-3
& ipsilateral nodes pN0-pN3b (rcvd. adjuv chemo), ER+ &/or PgR+, post-meno, completed 5 yrs Arom Inhib
or Tamox + AI; Letrozole vs placebo for prolonging survival
NSABP B-40: Protocol Summary |
Consent Form
Neoadj., T2-3, Nx/N0-cN2a, M0, HER2-; Capecitabine + Docetaxel or Gemcitabine
+ Docetaxel prior to AC +/- Bevacizumab (6 regimens) + Correlative Science
Studies → Surgery → Post-Op Bevacizumab (pre-op Bevacizumab regimens only)
SWOG S0307: Protocol Summary |
Consent Form
Adj., Stg I, II, III, Zoledronic Acid vs Clodronate vs Ibandronate (+ standard adjuv tx)
SWOG S0221: Protocol Summary |
Consent Form
Adj., Stg I, II, III, Node+ or Hi-Risk
Node -, male pts allowed; Continuous Schedule Doxorubicin+Cyclophosphade+GCSF vs q2wk Doxorubicin+Cyclophosphade,
both ! Taxol
(q2wks vs weekly x 12 wks)
NSABP B-39: Protocol Summary |
Consent Form
Adj., Stg. 0, I, II; Conventional Whole Breast RT vs Partial Breast RT (Multi-Catheter, Mammosite, or 3D-CRT)
(Sites need approval - check RT requirements in protocol.)
CALGB 40101: Protocol Summary |
Consent Form
Adj., T1‑4, N0-3, M0; Cyclophosphamide + Doxorubicin vs Paclitaxel
Stage III
CALGB 40101: Protocol Summary |
Consent Form
Adj., T1‑4, N0-3, M0; Cyclophosphamide + Doxorubicin vs Paclitaxel
NSABP B-44-I: Protocol Summary |
Pre-Randomization (HER2) Consent |
Treatment Consent Form
Adj., Stgs I-III, HER2(+), Node(+) or High Risk Node(-);
Taxol + Carboplatin + Trastuzumab
! Trastuzumab +/-
Bevacizumab (Industry trial - participation limited to 2 institutions –
only SLH currently approved.)
CTSU N063D:
Protocol Summary |
Consent Form
(Neo-)Adj., known ER/PgR or ER, HER2+, must have rcvd
>4 cycles of
anthracycline-based (neo-)adj chemo;
Eval of
sequences of Lapatinib &/or Trastuzumab (randomized
arms). Effective 3/15/09, Design 1 is closed.
ACOSOG Z1031:
Protocol Summary |
Consent Form
Supplemental Sample Consent |
Optional Genome Research Consent
Neoadj., T2-4c, any N, M0, Post-meno, ER+; 16-18 wks
Exemestane vs Letrozole vs Anastrozole
NSABP B-41:
Protocol Summary |
Consent Form
Neoadj.,
Stgs IIA-B & selected Stg IIIA, HER2+, palpable & operable; AC
! Taxol +
Trastuzumab vs AC
! Taxol + Lapatinib vs
AC
! Taxol + Trastuzumab + Lapatinib
(all Arms followed by Surg & post-surg Trastuzumab, & required correlative
studies for path CR)
NSABP B-42: Protocol Summary |
Consent Form
Adj. or Neoadj., Stg I, II, IIIA (rcvd. neoadjuv chemo) or prim tumor T1-3
& ipsilateral nodes pN0-pN3b (rcvd. adjuv chemo), ER+ &/or PgR+, post-meno, completed 5 yrs Arom Inhib
or Tamox + AI; Letrozole vs placebo for prolonging survival
SWOG S0307: Protocol Summary |
Consent Form
Adj., Stg I, II, III, Zoledronic Acid vs Clodronate vs Ibandronate (+ standard adjuv tx)
SWOG S0221: Protocol Summary |
Consent Form
Adj., Stg I, II, III, Node+ or Hi-Risk
Node -, male pts allowed; Continuous Schedule Doxorubicin+Cyclophosphade+GCSF vs q2wk Doxorubicin+Cyclophosphade,
both ! Taxol
(q2wks vs weekly x 12 wks)
CALGB
40502: Protocol Summary |
Consent Form
Stg IIIB or IV, known HER-2/neu, ER, & PgR status; 1st-line
randomized trial of Paclitaxel vs
Nanoparticle Albumin-Bound Paclitaxel + Bevacizumab vs Ixabepilone +
Bevacixumab (all given
weekly)
NSABP B-40: Protocol Summary |
Consent Form
Neoadj., T2-3, Nx/N0-cN2a, M0, HER2-; Capecitabine + Docetaxel or Gemcitabine
+ Docetaxel prior to AC +/- Bevacizumab (6 regimens) + Correlative Science
Studies ! Surgery ! Post-Op Bevacizumab (pre-op Bevacizumab regimens only)
Recurrent/Metastatic
CALGB
40502: Protocol Summary |
Consent Form
Stg IIIB or IV, known HER-2/neu, ER, & PgR status; 1st-line
randomized trial of Paclitaxel vs
Nanoparticle Albumin-Bound Paclitaxel + Bevacizumab vs Ixabepilone +
Bevacixumab (all given
weekly)
SWOG S0226: Protocol Summary |
Consent Form
Mets or Prog; Post-Menopausal; Anastrozole +/-
Fulvestrant as First-Line Therapy
TOP
Cancer Control
Cancer Control: Any Site
RTOG 0433: Protocol Summary |
Consent Form
Bone Mets; Single vs Multiple Fractions for Re-Irradiation
SWOG S0702: Protocol Summary |
Consent Form
Bone Mets
from any site, plan to receive Zoledronic acid; Observational study of ONJ
URCC U1701: Protocol Summary |
Consent Form
Any cancer dx, must receive chemo at least next 4 wks; Buspirone vs placebo to control dyspnea
Cancer Control: Breast
RTOG 0517: Protocol Summary |
Consent Form
BONE METS (from Breast, Lung, Prostate), must complete EBRT <14 days pre-regist, chemo or hormonal
therapy allowed; Zometa+Vit D+Ca +/- Single Dose Sr-89 or Sm-153
URCC U1105: Protocol Summary |
Consent Form
No prior chemo, planned Cisplatin, Carboplatin, Oxaliplatin, Doxorubicin,
or Epirubicin-containing regimen w/o
concurrent RT or IFN; 4 Double-blind regimens for preventing delayed nausea
CALGB 70301: Protocol Summary |
Consent Form
Companion Study to CALGB 40101; QOL, Employment & Informal Care Cost Analysis
Cancer Control: GU
RTOG 0517: Protocol Summary |
Consent Form
BONE METS (from Breast, Lung, Prostate), must complete EBRT <14 days pre-regist, chemo or hormonal
therapy allowed; Zometa+Vit D+Ca +/- Single Dose Sr-89 or Sm-153
Cancer Control: Gyn
GOG 0215: Protocol Summary |
Consent Form
Incr genetic risk of ovarian ca & electing risk-reducing surg (minimum removal of both ovaries); Zoledronic Acid vs Observ on Bone Mineral Density in Lumbar Spine
Cancer Control: Lung
RTOG 0517: Protocol Summary |
Consent Form
BONE METS (from Breast, Lung, Prostate), must complete EBRT <14 days pre-regist, chemo or hormonal
therapy allowed; Zometa+Vit D+Ca +/- Single Dose Sr-89 or Sm-153
SWOG E5597: Protocol Summary |
Consent Form
NSC, Resected Stage IA or IB; Selenium Supplementation as Chemoprevention
SWOG S0424: Protocol Summary |
Consent Form
Molecular Epidemiology Study; NSCLC in Smoking &
Non-Smoking Men/Women
Cancer Control: Lymphoma
SWOG 8819: Protocol Summary
(no consent form)
Path Companion to SWOG-coordinated protocols for prev untreated, NH
lymphoma
TOP
GI
Also, see
Cancer Control section for symptom
management/prevention trials.
Colorectal
CTSU N0147: Protocol Summary |
Consent Form
COLORECTAL, Stg III, Post-Curative Resec; Oxal + 5FU /Leuc +/- Cetuximab
CALGB 80405: Protocol Summary |
Consent Form
COLORECTAL, Adenocarcinoma (Adv or Mets), Untreated, Wild
type K-ras (determined pre-regist ); Either FOLFOX or FOLFIRI with either
Bevacizumab or Cetuximab or w/combined Bevacizumab & Cetuximab
Rectal
NSABP R-04: Protocol Summary |
Consent Form
RECTAL, Stgs II-III, operable invasive adenocarcinoma; Pre-op RT + Capecitabine +/- Oxal vs Pre-op RT + CI 5-FU +/- Oxal
(RNALater specimens required)
RTOG 0822:
Protocol Summary |
Consent Form
RECTAL, T3-T4, N0-2, M0; Pre-op IMRT +
Concurrent Capecitabine & Oxaliplatin ! Surgery ! Post-Op FOLFOX
(Sites need approval – check RT
requirements in protocol)
Stomach
CALGB 80101: Protocol Summary |
Consent Form
STOMACH or GE Junction, Post-Resection, Stg IB (if N1 or tumor exten beyond muscularis propria), II, IIIA-B, IV (w/M0); Eval
of 2 Chemoradiation Regimens (Rapid Review required - check RT requirements)
Other
CALGB 80101: Protocol Summary |
Consent Form
STOMACH or GE Junction, Post-Resection, Stg IB (if N1 or tumor exten beyond muscularis propria), II, IIIA-B, IV (w/M0); Eval
of 2 Chemoradiation Regimens (Rapid Review required - check RT requirements)
TOP
GU
Also, see
Cancer Control section for symptom
management/prevention trials.
Prostate: Stage I
RTOG 0521: Protocol Summary |
Consent Form
PROSTATE, Localized Stgs I, II, III & select Stg IV (T4), High-Risk; Androgen Suppr + 3DCRT/IMRT +/- Docetaxel & Prednisone chemo
(Sites need approval - check RT requirements in protocol.)
Prostate: Stage II
RTOG 0521: Protocol Summary |
Consent Form
PROSTATE, Localized Stgs I, II, III & select Stg IV (T4), High-Risk; Androgen Suppr + 3DCRT/IMRT +/- Docetaxel & Prednisone chemo
(Sites need approval - check RT requirements in protocol.)
RTOG 0232: Protocol Summary |
Consent Form
PROSTATE, T1c-2b, Nx/N0, M0; Ext Beam RT+Transperineal
Interstitial Permanent Brachytherapy vs Brachytherapy alone (Sites need approval - check RT requirements in protocol.)
RTOG 0612: Protocol Summary |
Consent Form
PROSTATE, Markers of RT Outcome for Pts Enrolled on RTOG 0232
Prostate: Stage III
RTOG 0521: Protocol Summary |
Consent Form
PROSTATE, Localized Stgs I, II, III & select Stg IV (T4), High-Risk; Androgen Suppr + 3DCRT/IMRT +/- Docetaxel & Prednisone chemo
(Sites need approval - check RT requirements in protocol.)
Prostate: Stage IV
MDA ID-00156 : Protocol Summary |
Consent Form
PROSTATE,
Adenocarcinoma, Stg IV, Androgen-Indep; Induction Chemo ! Doxorubicin +/-
single dose
Strontium-89
SWOG S0421: Protocol Summary |
Consent Form
PROSTATE, Adenocarcinoma, Any T & N, M1b + bone mets, hormone refrac;
Docetaxel + Atrasentan vs Docetaxel + placebo
RTOG 0521: Protocol Summary |
Consent Form
PROSTATE, Localized Stgs I, II, III & select Stg IV (T4), High-Risk; Androgen Suppr + 3DCRT/IMRT +/- Docetaxel & Prednisone chemo
(Sites need approval - check RT requirements in protocol.)
CALGB 90202: Protocol Summary |
Consent Form
PROSTATE, Adenocarcinoma, >1 bone met; Early vs
Standard Zoledronic Acid to prevent skeletal-related events
Renal
CTSU E2805:
Protocol Summary |
Consent Form
RENAL, Resectable, no distant mets; Double-blind adjuv
Sunitinib vs Sorafenib vs placebo
TOP
GYN
Also, see
Cancer Control section for symptom
management/prevention trials.
Cervical: Stage I
GOG 0219: Protocol Summary |
Consent Form
CERVICAL, Stgs I-B2, II-A (>4cm), II-B, III-B, IV-A, primary, untreated, squamous, adenocarcinoma, or adenosquamous; Weekly Cisp+RT vs Cisp+Tirapazamine+RT
Cervical: Stage II
GOG 0219: Protocol Summary |
Consent Form
CERVICAL, Stgs I-B2, II-A (>4cm), II-B, III-B, IV-A, primary, untreated, squamous, adenocarcinoma, or adenosquamous; Weekly Cisp+RT vs Cisp+Tirapazamine+RT
Cervical: Stage III
GOG 0219: Protocol Summary |
Consent Form
CERVICAL, Stgs I-B2, II-A (>4cm), II-B, III-B, IV-A, primary, untreated, squamous, adenocarcinoma, or adenosquamous; Weekly Cisp+RT vs Cisp+Tirapazamine+RT
EndometrialGOG-0248:
Protocol Summary |
Consent Form
ENDOMETRIAL, Adv, Persis, or Recur; Weekly Temsirolimus vs Weekly Temsirolimus
+ alternating
Megestrol Acetate (x3wks) & Tamoxifen (x3wks)
GOG 0229F:
Protocol Summary |
Consent Form
ENDOMETRIAL, Recur or Persis, 1 prior chemotherapeutic
regimen for endometrial cancer required; Eval of VEGF-Trap
Ovarian: Stage III
GOG 0212: Protocol Summary |
Consent Form
OVARIAN (Adv, Epith) or PERITONEAL (Prim), CR after Prim Platinum/Taxane chemo; Maint Chemo (12 monthly cycles of Paclitaxel
or
CT-2103) vs No Tx until relapse
GOG 0235: Protocol Summary |
Consent Form
OVARIAN (Invasive, Epith), PERITONEAL (Prim), or
FALLOPIAN, Stgs III or IV, undergoing prim chemo; Longitudinal Study of YKL-40
Ovarian: Stage IV
GOG 0212: Protocol Summary |
Consent Form
OVARIAN (Adv, Epith) or PERITONEAL (Prim), CR after Prim Platinum/Taxane chemo; Maint Chemo (12 monthly cycles of Paclitaxel
or
CT-2103) vs No Tx until relapse
GOG 0235: Protocol Summary |
Consent Form
OVARIAN (Invasive, Epith), PERITONEAL (Prim), or
FALLOPIAN, Stgs III or IV, undergoing prim chemo; Longitudinal Study of YKL-40
Vulvar
GOG 0205: Protocol Summary |
Consent Form
VULVAR, Locally Adv, Prev Untreated, Squamous; RT + Weekly
Cisplatin
Other
GOG 0235: Protocol Summary |
Consent Form
OVARIAN (Invasive, Epith), PERITONEAL (Prim), or
FALLOPIAN, Stgs III or IV, undergoing prim chemo; Longitudinal Study of YKL-40
TOP
Head & Neck
Also, see
Cancer Control section for symptom
management/prevention trials.
RTOG 0619:
Protocol Summary |
Consent Form
ORAL CAVITY,
OROPHARYNX, LARYNX, HYPOPHARYNX (no lip, nasopharynx, sinuses), Squamous,
Post-op Stg
III-IV (pre-op stage I-IV); Chemoradiotherapy +/-
Vandetanib (Sites need approval – check RT requirements in protocol.)
RTOG 0514: Protocol Summary |
Consent Form
Head & Neck Cancer Tissue/Specimen Bank
TOP
Leukemia
Also, see Cancer Control section for symptom
management/prevention trials.
Acute
CALGB C10001: Protocol Summary |
Donor Consent |
Recipient Consent
ALL, Ph+, complete remission after tx on CALGB 10102;
Sequential Chemo+Gleevec+Transplantation (Only SLH is currently approved
for BMT. QARC approval required for TBI.)
SWOG S0333: Protocol Summary |
Consent Form
ALL, Non-L3, New Dx, age <65; double Induction Chemo ! Consolid
Chemo ! Maint Chemo
SWOG S0106: Protocol Summary |
Consent Form
AML (non-M3), DeNovo, age <61, no prior tx; Daunomycin
+ Ara-C +/- Mylotarg Induction ! Ara-C Consolid ! Post-Consolid Mylotarg or No
Additional Therapy
CTSU E2902:
Protocol Summary |
Consent Form
AML, >2nd remission or
remission after prim induction failure or >age 60 in 1st remission;
R115777 (Zarnestra) vs Observ
Chronic
CALGB 10404:
Protocol Summary |
Consent Form
CLL (B-cell), symptomatic & active intermediate or
high-risk Rai staging, no prior tx; Randomized study of 3 Fludarabine/Antibody
Combinations
CTSU E2905:
Protocol Summary |
Consent Form
MDS or non-proliferative CMML, Low- or Intermediate-1-risk, symptomatic
anemia; Frequency of Major Erythroid
Response to
Lenalidomide +/- Epoetin Alfa
Ancillary
SWOG 9007: Protocol Summary |
Consent Form
MANDATORY Cytometry Companion to all Leukemia tx protocols
CALGB 9862: Protocol Summary |
Consent Form
Molecular
Genetic study for prev untreated ALL; MANDATORY for CALGB tx trials
SWOG S9910: Protocol Summary |
Consent Form
Ancillary; specimen submission to Centralized Reference Lab & Tissue Repository
CALGB 8461: Protocol Summary |
Consent Form
Cytogenetics study for prev untreated AML, ALL, MDS
CALGB 9665: Protocol Summary |
Consent Form
Tissue Bank for prev untreated leukemia pts (acute or chronic) & MDS
CALGB 9760: Protocol Summary |
Consent Form
Multidrug Resistance studies for prev untreated AML & ALL
TOP
LungAlso, see
Cancer Control section for symptom
management/prevention trials.
NSC: Stage IIIA
RTOG 0617:
Protocol Summary |
Consent Form
NSC, Stgs IIIA-B (Unresectable), M0; Stand Dose
(60Gy) vs High-Dose (74Gy) Conformal RT + Concurrent & Consolidation Carbo/Taxol
+/- Cetuximab (Sites need approval – check RT requirements in protocol)
NSC: Stage IIIB
RTOG 0617:
Protocol Summary |
Consent Form
NSC, Stgs IIIA-B (Unresectable), M0; Sted approval – check RT requirements in protocol)
CALGB 30607:
Protocol Summary |
Consent Form
NSC, Stg IIIB-IV, must have rcvd 4 cycles of
platinum-based chemo +/- Bevacizumab & had
no progression; Eval of
Sunitinib vs placebo
NSC: Stage IV
CALGB 30607:
Protocol Summary |
Consent Form
NSC, Stg IIIB-IV, must have rcvd 4 cycles of
platinum-based chemo +/- Bevacizumab & had
no progression; Eval of
Sunitinib vs placebo
RTOG 0320:
Protocol Summary |
Consent Form
NSC, 1-3 Brain Mets; Whole Brain RT+Stereotactic Radiosurgery +/- Temozolomide or Erlotinib (each treating
facility must have an RTOG-approved Stereotactic RT Facility Questionnaire for
this study)
NSC: Advanced / Progressive
CTSU N0723:
Protocol Summary |
Consent Form
NSC, Adv or Prog;
Central Path Review & FISH pre-regist, Biomarker Validation of 2nd line therapy (Erlotinib)
in pts
randomized to Pemetrexed vs Erlotinib
Ancillary
SWOG S9925: Protocol Summary
(no consent form)
Ancillary, Specimen Repository Companion
TOP
Lymphoma
Also, see
Cancer Control section for symptom
management/prevention trials.
Non-Hodgkin's
CALGB 50401: Protocol Summary |
Consent Form
NH, Not Rituximab-refractory, Grade 1, 2, or 3a, Follicular; Lenalidomide vs Rituximab + Lenalidomide
Ancillary
SWOG 8947: Protocol Summary |
Consent Form
Serum Companion to SWOG-coord protocols for prev untreated, NH lymphoma
TOP
Myeloma
Also, see
Cancer Control section for symptom
management/prevention trials.
SWOG S0120: Protocol Summary |
Consent Form
MGUS, asymptomatic Myeloma, or Solitary Plasmacytoma, not requiring tx;
Observational Biologic Study (BM aspir & Perip Blood)
CALGB 100104:
Protocol Summary |
Consent Form
MM, Durie-Salmon Stg
>1, stable or responsive to >2 mos of any
induction therapy; Autologous
PBSCT ! Maintenance CC-5013/placebo
(Only SLH is currently
approved for BMT.)
SWOG S0309: Protocol Summary
Ancillary, Specimen Repository Protocol
TOP
Misc.
CTSU E1Y03: Protocol Summary |
Consent Form
Master Protocol; Pharmacogenetic & Genomic Studies
|